
UCB has partnered with Synosia Therapeutics to develop two of the Swiss firm’s compounds for Parkinson’s disease. Basel-based Synosia has …
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

